Antidepressants for depression in stage 3-5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP)

Nephrology Dialysis Transplantation

Volumn 27, Issue 10, 2012, Pages 3736-3745

  Nagler, Evi V ^a,b   Webster, Angela C ^b,c,d   Vanholder, Raymond ^a   Zoccali, Carmine ^e  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e CNR   (Italy)

Author keywords

antidepressive agents; depressive disorder, major; renal insufficiency; systematic review

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMITRIPTYLINOXIDE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DIBENZEPIN; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MELITRACEN; MIANSERIN; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; PROTRIPTYLINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

CHRONIC KIDNEY DISEASE; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DSM-IV; EVENING DOSAGE; HEMODIALYSIS; HUMAN; HYPOTENSION; MAJOR DEPRESSION; MORNING DOSAGE; NAUSEA; PERITONEAL DIALYSIS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; EUROPE; HUMANS; KIDNEY FAILURE, CHRONIC; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84868591546     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs295     Document Type: Review

References (72)

1. Rayner L, Price A, Evans A et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev 2010; 3: CD007503
2. Levy NB, Blumenfield M, Beasley CM, Jr et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. Gen Hosp Psychiatr 1996; 18: 8-13
3. Kamo T, Horikawa N, Tsuruta Y et al. Efficacy and pharmacokinetics of fluvoxamine maleate in patients with mild depression undergoing hemodialysis. Psychiatr Clin Neurosci 2004; 58: 133-137
4. Kennedy SH, Craven JL, Rodin GM. Major depression in renal dialysis patients: an open trial of antidepressant therapy. J Clin Psychiatr 1989; 50: 60-63
5. Kalender B, Ozdemir AC, Yalug I et al. Antidepressant treatment increases quality of life in patients with chronic renal failure. Renal Failure 2007; 29: 817-822
6. Lee SK, Lee HS, Lee TB et al. The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. J Korean Med Sci 2004; 19: 384-389
7. Koo JR, Yoon JY, Joo MH et al. Treatment of depression and effect of antidepression treatment on nutritional status in chronic hemodialysis patients. Am J Med Sci 2005; 329: 1-5
8. Turk S, Atalay H, Altintepe L et al. Treatment with antidepressive drugs improved quality of life in chronic hemodialysis patients. Clin Nephrol 2006; 65: 113-118
9. Wuerth D, Finkelstein SH, Kliger AS et al. Chronic peritoneal dialysis patients diagnosed with clinical depression: results of pharmacologic therapy. Semin Dialysis 2003; 16: 424-427
10. Atalay H, Solak Y, Biyik M et al. Sertraline treatment is associated with an improvement in depression and health-related quality of life in chronic peritoneal dialysis patients. Int Urol Nephrol 2010; 42: 527-536
11. Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatr 2010; 71(Suppl E1): e04
12. Darowski A, Chambers SA, Chambers DJ. Antidepressants and falls in the elderly. Drugs Aging 2009; 26: 381-394
13. American Psychiatric A. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association, 1994
14. Cukor D, Coplan J, Brown C et al. Depression and anxiety in urban hemodialysis patients. Clin J Am Soc Nephrol 2007; 484-490
15. Lopes AA, Albert JM, Young EWet al. Screening for depression in hemodialysis patients: associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int 2004; 66: 2047-2053
16. Hedayati SS, Finkelstein FO. Epidemiology, diagnosis, and management of depression in patients with CKD. Am J Kidney Dis 2009; 54: 741-752
17. Raymond CB, Wazny LD, Honcharik PL. Pharmacotherapeutic options for the treatment of depression in patients with chronic kidney disease. Nephrol Nurs J 2008; 35: 257-263
18. Kimmel PL, Cohen SD, Peterson RA. Depression in patients with chronic renal disease: where are we going? J Ren Nutr 2008; 18: 99-103
19. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004; 1: CD003012.
20. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000; 14: 3-20
21. Vanholder R, Van Landschoot N, De Smet R et al. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 1988; 33: 996-1004
22. Cohen LM, Tessier EG, Germain MJ et al. Update on psychotropic medication use in renal disease. [Review] [101 refs]. Psychosomatics 2004; 45: 34-48
23. Blumenfield M, Levy NB, Spinowitz B et al. Fluoxetine in depressed patients on dialysis. Int J Psychiatr Med 1997; 27: 71-80
24. Pervin E, Yazici A, Baflterzi AD et al. Escitalopram treatment of major depression in patients undergoing hemodialysis [Abstract]. 2006 World Psychiatric Association, International Congress, Istanbul, Turkey, July 12-16, 2006
25. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation. Am J Kidney Dis 2002; 39: S1-S1000
26. Joint Formulary Committee. British National Formulary. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2010
27. American Hospital Formulary Service. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 2010.
28. Commissie Farmaceutische Hulp van het College voor zorgverzekeringen. Farmacotherapeutisch Kompas. Utrecht: College voor zorgverzekeringen, 2010.
29. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. www.cochrane-handbook.org
30. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012
31. Sweetman SC. Martindale: The Complete Drug Reference. London: Pharmaceutical Press, 2010
32. Porter RS (ed.). The Merck Manual of Diagnosis and Therapy. Hoddesdon, Hertfortshire, UK: Merck Sharp & Dohme Limited, 2010
33. Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten. 2010. http://www.fagg-afmps.be
34. Anttila M, Sotaniemi EA, Pelkonen O et al. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther 2005; 77: 54-62
35. Aronoff GR, Bergstrom RF, Pottratz ST et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984; 36: 138-144
36. Barbhaiya RH, Brady ME, Shukla UA et al. Steady-state pharmacokinetics of nefazodone in subjects with normal and impaired renal function. Eur J Clin Pharmacol 1995; 49: 229-235
37. Barbhaiya RH, Shukla UA, Greene DS. Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment. Eur J Clin Pharmacol 1995; 49: 221-228
38. Bengtsson F, Hoglund P, Timmer C et al. Mirtazapine oral single dose kinetics in patients with different degrees of renal failure. Hum Psychopharm 1998; 13: 357-365
39. Catanese B, Dionisio A, Barillari G et al. A comparative study of trazodone serum concentrations in patients with normal or impaired renal function. Boll Chim Farm 1978; 117: 424-427
40. Coulomb F, Ducret F, Laneury JP et al. Pharmacokinetics of singledose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol 2000; 40: 482-487
41. Dawling S, Lynn K, Rosser R et al. The pharmacokinetics of nortriptyline in patients with chronic renal failure. Brit J Clin Pharmacol 1981; 12: 39-45
42. Dawling S, Lynn K, Rosser R et al. Nortriptyline metabolism in chronic renal failure: metabolite elimination. Clin Pharmacol Ther 1982; 32: 322-329
43. Degen J, Wolke E, Seiberling M et al. [Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure] [Article in German]. Med Klin 88: 129-133
44. Doweiko J, Fogel BS, Goldberg RJ. Trazodone and hemodialysis. J Clin Psychiatr 1984; 45: 361
45. Doyle GD, Laher M, Kelly JG et al. The pharmacokinetics of paroxetine in renal impairment. Acta Psychiatr Scand Suppl 1989; 350: 89-90
46. Faulkner RD, Senekjian HO, Lee CS. Hemodialysis of doxepin and desmethyldoxepin in uremic patients. Artif Organs 1984; 8: 151-155
47. Joffe P, Larsen FS, Pedersen V et al. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998; 54: 237-242
48. Lemberger L, Bergstrom RF, Wolen RL et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatr 1985; 46: 14-19
49. Lieberman JA, Cooper TB, Suckow RF et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985; 37: 301-307
50. Lynn K, Braithwaite R, Dawling S et al. Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis. Eur J Clin Pharmacol 1981; 19: 73-77
51. Puozzo C, Pozet N, Deprez D et al. Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab 1998; 23: 280-286
52. Royer RJ, Albin H, Barrucand D et al. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. Clin Neuropharmacol 1988; 11: S90-S96
53. Salvadori C, Merdjan H, Brouard R et al. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis. Fund Clin Pharmacol 1990; 4: 663-671
54. Schlotterbeck PM, Vehren T, Milenovic S et al. No influence of dialysis on mirtazapine-a case report. Pharmacopsychiatr 2008; 41: 259-260
55. Schoerlin MP, Horber FF, Frey FJ et al. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol 1990; 30: 272-284
56. Schwenk MH, Verga MA, Wagner JD. Hemodialyzability of sertraline. Clin Nephrol 1995; 44: 121-124
57. Spigset O, Hagg S, Stegmayr B et al. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000; 56: 699-703
58. Stoeckel K, Pfefen JP, Mayersohn M et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand Suppl 1990; 360: 94-97
59. Tasset JJ, Singh S, Pesce AJ. Evaluation of amitriptyline pharmacokinetics during peritoneal dialysis. Ther Drug Monit 1985; 7: 255-257
60. Troy SM, Schultz RW, Parker VD et al. The effect of renal disease on the disposition of venlafaxine. Clin Pharmacol Ther 1994; 56: 14-21
61. Turpeinen M, Koivuviita N, Tolonen A et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Brit J Clin Pharmacol 2007; 64: 165-173
62. Worrall SP, Almond MK, Dhillon S. Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron 2004; 97: c83-c89
63. Nichols AJ, Richards LS, Behrle JA et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharm Ther 2011; 1: 3-13
64. Wuerth D, Finkelstein SH, Ciarcia J et al. Identification and treatment of depression in a cohort of patients maintained on chronic peritoneal dialysis. Am J Kidney Dis 2001; 37: 1011-1017
65. Wuerth D, Finkelstein SH, Finkelstein FO. The identification and treatment of depression in patients maintained on dialysis. Semin Dial 2005; 18: 142-146
66. Fouque D, Vennegoor M, ter WP et al. EBPG guideline on nutrition. Nephrol Dial Transplant 2007; 22 (Suppl 2): ii45-ii87
67. Fukunishi I, Kitaoka T, Shirai T et al. Cardiac arrest caused by maprotiline in an elderly hemodialysis patient. Nephron 1998; 78: 225
68. Kunishima Y, Masumori N, Kadono M et al. A case of neuroleptic malignant syndrome in a patient with hemodialysis. Int J Urol 2000; 7: 62-64
69. Sunderrajan S, Brooks CS, Sunderrajan EV. Nortriptyline-induced severe hyperventilation. Arch Int Med 1985; 145: 746-747
70. Momen MN, Sebastian CS, Buckley PF. Paradoxical reaction to fluoxetine. Psychosomatics 2003; 44: 259-260
71. Iraqi AH. A case report of paranoid delusion with venlafaxine use. J Am Ger Soc 2003; 51: 1045-1046
72. Craven JL, Rodin GM, Littlefield C. The Beck Depression Inventory as a screening device for major depression in renal dialysis patients. Int J Psychiatr Med 1988; 18: 365-374